Workers in aquaculture plant
FeedKind®
Calysta’s FeedKind® single cell protein has received full approval for use in fish and shrimp feeds after an extensive evaluation process by the Ministry of Agriculture and Rural Affairs (MARA) of China.
Calysta and Adisseo partnered to produce FeedKind for the Asian aquaculture market and will deliver the first product to customers through the Adisseo sales network in the country.
The protein is produced by harnessing the power of a naturally occurring microbe that converts methane into a feed ingredient. The production plant is located in Chongqing.
Sun Bin, Calysseo’s Chairman, said: "This is an important step forward not just in helping make food production systems more sustainable, but in improving global food security, by providing feed producers with a domestically-produced, reliable feed ingredient that isn’t susceptible to weather or climate-driven fluctuations in supply."
According to a statement released by FeedKind®, research has proved "distinct benefits for shrimp, concluding that it promotes strong, healthy growth, while also helping activate shrimp’s immune response to Vibrio, the causative agent of Early Mortality Syndrome."
In addition, Herman Hong, Adisseo Aquaculture Manager for China noted: "This is a significant step forward for the adoption and use of fermented proteins across global food systems. MARA approval is more than simply a regulatory step, it is validation that our product is a healthy and practical ingredient for use in aquaculture systems and opens the door for the Chinese aquaculture sector to set new standards in sustainable feed practices."
Finally, Alan Shaw, co-founder and CEO of Calysta confirmed: "Approval from MARA is the final piece of the puzzle to bring a truly sustainable, high-quality source of protein to the Asian aquaculture market that offers superior nutrition to existing alternatives. FeedKind® can be produced year-round using no arable land and without using any plant or animal ingredients, it truly is a protein without limits."
